SAN DIEGO, Jun 03, 2010 (BUSINESS WIRE) --Illumina, Inc. (NASDAQ: ILMN) today announced a new price of $19,500 for its individual genome sequencing service. In addition, the company announced a price of $14,500 per genome for groups of five or more participants using the same physician. Individuals with serious medical conditions for whom whole-genome sequencing could provide potential direct clinical value will be eligible for special pricing of $9,500 per genome. In all cases, the service requires individuals to follow Illumina's physician-mediated process, which involves pre-service consultation, consent, and a seven-day cooling off period, with final genome data returned to the physician.
"We are very excited to be able to offer improved pricing for our individual genome sequencing service, as technological advancements continue to drive down costs," said Jay Flatley, president and chief executive officer of Illumina. "We are also pleased to be able to offer special pricing programs that will serve to further increase access to individual genome sequencing. If we can stimulate the generation of more individual whole-genome sequences and the comparison of those sequences to the public databases being populated by academia, the content of the databases can be enriched and the entire field accelerated."
Illumina also announced its intention to create the World Genome Registry, a web-based resource for those who have been sequenced to record the date they were sequenced, at what coverage and with which technology platform. This web site will serve to keep the consumer genetics community updated on the current global numbers and status of individual whole-genome human sequences being generated. The company intends to create this resource and then turn it over to the community once it is established.
A world leader in genotyping, gene expression and whole-genome sequencing, Illumina launched its individual genome sequencing service in June 2009. The service is built around physician-patient consultation, with a physician's order required to initiate the process. Sequencing is performed in Illumina's CLIA-certified, CAP-accredited laboratory, following a rigorous process that focuses on physician involvement, patient privacy and data quality. More information about Illumina's individual genome sequencing service and process can be found at http://www.illumina.com/everygenome.
About Illumina
Illumina (http://www.illumina.com) is the leading developer, manufacturer, and marketer of life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which can enhance drug discovery and clinical research, allow diseases to be detected earlier, and may eventually permit better choices of drugs for individual patients.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding our intention to create the World Genome Registry. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product and service introductions and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Senior Manager, Public Relations
858-882-6822
wgrabill@illumina.com
